Drew W. Rasco

TL;DR: Pembrolizumab was well tolerated and associated with durable antitumor activity in multiple solid tumors, and Mechanism-based translational models with a focus on intratumor exposure prediction suggested robust clinical activity would be observed at doses ≥2 mg/kg every 3 weeks.

TL;DR: Abemaciclib represents the first selective inhibitor of CDK4 and CDK6 with a safety profile allowing continuous dosing to achieve sustained target inhibition, and this first-in-human experience demonstrates single-agent activity for patients with advanced breast cancer, NSCLC, and other solid tumors.

TL;DR: The results suggest that dual inhibition of both pathways may potentially exhibit favorable efficacy compared with inhibition of either pathway, at the expense of greater toxicity.

TL;DR: Lenvatinib plus pembrolizumab showed anti-tumour activity in patients with advanced recurrent endometrial cancer with a safety profile that was similar to those previously reported for lenvatinIB and pembrology monotherapies, apart from an increased frequency of hypothyroidism.

TL;DR: 5F9 is well tolerated using a priming dose at 1mg/kg on day 1 followed by maintenance doses of up to 45 mg/kg weekly, and the half-life of approximately 13 days was observed.